By IDSE News Staff
A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system.
This was the first clinical trial of any subunit TB vaccine candidate in a thermostable form (Nature Commun 2023 DOI: 10.1038/s41467-023-36789-2).
The experimental vaccine, ID93+GLA-SE, was developed by Christopher B. Fox, PhD, and scientists at